Functional dyspepsia

Current Opinion in Gastroenterology

Volumn 27, Issue 6, 2011, Pages 549-557

  Tack, Jan ^a   Masaoka, Tatsuhiro ^a   Janssen, Pieter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

acotiamide; brain gut axis; functional dyspepsia; gastric accommodation; gastric motility; gastroprokinetic drugs; quality of life; visceral sensitivity

Indexed keywords

ACOTIAMIDE; ACTIVATED CARBON; DIGESTIVE TRACT AGENT; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FUNDUS RELAXING DRUG; JAPANESE MEDICINE; LANSOPRAZOLE; MAGNESIUM OXIDE; MOSAPRIDE; PLACEBO; PROKINETIC AGENT; SEROTONIN 4 AGONIST; SIMETHICONE; TEGASEROD; UNCLASSIFIED DRUG;

DISEASE SEVERITY; DISTRESS SYNDROME; DUODENUM; DYSPEPSIA; EPIGASTRIC PAIN; FUNCTIONAL DISEASE; FUNCTIONAL DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GENETIC SUSCEPTIBILITY; HUMAN; HYPERSENSITIVITY; INFLAMMATION; IRRITABLE COLON; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL DISTRESS SYNDROME; POSTPRANDIAL STATE; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; REVIEW; STOMACH FUNDUS; STOMACH MOTILITY; STOMACH PARESIS; TRADITIONAL MEDICINE;

DYSPEPSIA; HUMANS;

EID: 80054700044     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32834b7ca8     Document Type: Review

References (70)

1. Parkman HP, Camilleri M, Farrugia G, et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol Motil 2010;22:113-133.
2. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479.
3. Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology 2010;138:1302-1311. A population-based study of subtypes of functional dyspepsia.
4. Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology 2009;137:94-100.
5. Manabe N, Haruma K, Hata J, et al. Clinical characteristics of Japanese dyspeptic patients: is the Rome III classification applicable? Scand J Gastroenterol 2010;45:567-572.
6. VanOudenhove L, Holvoet L, Vandenberghe J, et al. Do we have an alternative for the Rome III gastroduodenal symptom-based subgroups in functional gastroduodenal disorders? A cluster analysis approach. Neurogastroenterol Motil 2011;23:730-738.
7. Ohara S, Kawano T, Kusano M, Kouzu T. Survey on the prevalence of GERD and FD based on the Montreal definition and the Rome III criteria among patients presenting with epigastric symptoms in Japan. J Gastroenterol 2011;46:603-611.
8. Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol 2010;105:2626-2631.
9. Parkman HP, Yates K, Hasler WL, et al., National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 2011;140:101-115. A large study of clinical features of idiopathic gastroparesis patients presenting to major academic centers in the USA.
10. Janssen P, van Oudenhove L, Bisschops R, Tack J. Idiopathic gastroparesis or functional dyspepsia with delayed gastric emptying: where is the difference? Gastroenterology 2011;140:2145-2146.
11. Brook RA, Kleinman NL, Choung RS, et al. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol 2010;8:498-503. A study of the socioeconomic impact of functional dyspepsia.
12. Aro P, Talley NJ, Agreus L, et al. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther 2011;33:1215-1224.
13. Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol 2010;25:1151-1156.
14. Lee HJ, Lee SY, Kim JH, et al. Depressive mood and quality of life in functional gastrointestinal disorders: differences between functional dyspepsia, irritable bowel syndrome and overlap syndrome. Gen Hosp Psychiatry 2010;32:499-502.
15. Lacy BE, Everhart K, Crowell MD. Functional dyspepsia is associated with sleep disorders. Clin Gastroenterol Hepatol 2011;9:410-414.
16. Van Oudenhove L, Vandenberghe J, Vos R, et al. Factors associated with co-morbid irritable bowel syndrome and chronic fatigue-like symptoms in functional dyspepsia. Neurogastroenterol Motil 2011;23:524-e202.
17. Van Oudenhove L, Vandenberghe J, Vos R, et al. Risk factors for impaired health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2011;33:261-274.
18. Haag S, Senf W, Tagay S, et al. Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia? Neurogastroenterol Motil 2010;22:262-e79.
19. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Thjodleifsson B. Natural history of functional dyspepsia: a 10-year population-based study. Digestion 2010;81:53-61.
20. Kindt S, Van Oudenhove L, Mispelon L, et al. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol 2011;106:340-348. A study of the long-term outcome of tertiary care functional dyspepsia patients.
21. Tack J, Talley NJ. Gastroduodenal disorders. Am J Gastroenterol 2010;105:757-763.
22. Hammer J, Eslick GD, Howell SC, et al. Diagnostic yield of alarm features in irritable bowel syndrome and function dyspepsia. Gut 2004;53:666-672. (Pubitemid 38561444)
23. Canan O, Ozcay F, Ozbay-Hosnut F, et al. Value of the Likert dyspepsia scale in differentiation of functional and organic dyspepsia in children. J Pediatr Gastroenterol Nutr 2011;52:392-398.
24. Tam YH, Chan KW, To KF, et al. Impact of pediatric Rome III criteria of functional dyspepsia on the diagnostic yield of upper endoscopy and predictors for a positive endoscopic finding. J Pediatr Gastroenterol Nutr 2011;52:387-391.
25. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-1255. (Pubitemid 39345892)
26. Sarnelli G, Caenepeel P, Geypens B, et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003;98:783-788. (Pubitemid 36576302)
27. Manabe N, Nakamura K, Hara M, et al. Impaired gastric response to modified sham feeding in patients with postprandial distress syndrome. Neurogastroenterol Motil 2011;23:215-219; e112.
28. Kusano M, Moki F, Hosaka H, et al. Gastroptosis is associated with less dyspepsia, rather than a cause of dyspepsia, in Japanese persons. Intern Med 2011;50:667-671.
29. Delgado-Aros S, Camilleri M, Cremonini F, et al. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology 2004;127:1685-1694. (Pubitemid 39575847)
30. Kusano M, Zai H, Shimoyama Y, et al. Rapid gastric emptying, rather than delayed gastric emptying, might provoke functional dyspepsia. J Gastroenterol Hepatol 2011;26(Suppl 3):75-78.
31. Tack J, Bisschops R. Mechanisms underlying meal-induced symptoms in functional dyspepsia. Gastroenterology 2004;127:1685-1694.
32. Bharucha AE, Manduca A, Lake DS, et al. Gastric motor disturbances in patients with idiopathic rapid gastric emptying. Neurogastroenterol Motil 2011;23:617-e252.
33. Lee KJ, Tack J. Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil 2010;16:251-257.
34. Ishii M, Kusunoki H, Manabe N, et al. Evaluation of duodenal hypersensitivity induced by duodenal acidification using transnasal endoscopy. J Gastroenterol Hepatol 2010;25:913-918.
35. Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68 double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol 2010;105:1835-1842. This study demonstrates the presence of low-grade duodenal inflammation in patients with postinfectious functional dyspepsia.
36. Li X, Chen H, Lu H, et al. The study on the role of inflammatory cells and mediators in postinfectious functional dyspepsia. Scand J Gastroenterol 2010;45:573-581.
37. Kindt S, Tertychnyy A, de Hertogh G, et al. Intestinal immune activation in presumed postinfectious functional dyspepsia. Neurogastroenterol Motil 2009;21:832-e56.
38. Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy: an association with allergy and functional dyspepsia. Aliment Pharmacol Ther 2010;31:1229-1236.
39. Neilan NA, Dowling PJ, Taylor DL, et al. Useful biomarkers in pediatric eosinophilic duodenitis and their existence: a case-control, single-blind, observational pilot study. J Pediatr Gastroenterol Nutr 2010;50:377-384.
40. Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011;106:1089-1098. This study demonstrates systemic signs of low-grade inflammation in functional dyspepsia, and this is associated with delayed gastric emptying.
41. Van Oudenhove L, Vandenberghe J, Dupont P, et al. Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: a H (2) (15) O-PET study. Am J Gastroenterol 2010;105:913-924.
42. Van Oudenhove L, Vandenberghe J, Dupont P, et al. Regional brain activity in functional dyspepsia: a H (2) (15) O-PET study on the role of gastric sensitivity and abuse history. Gastroenterology 2010;139:36-47. Altered cortical responses to gastric balloon distension in functional dyspepsia patients with visceral hypersensitivity, and this is associated with delayed gastric emptying.
43. Ameloot K, Janssen P, Scarpellini E, et al. Endocannabinoid control of gastric sensorimotor function in man. Aliment Pharmacol Ther 2010;31:1123-1131.
44. Janssen P, Pottel H, Vos R, Tack J. Endogenously released opioids mediate meal-induced gastric relaxation via peripheral mu-opioid receptors. Aliment Pharmacol Ther 2011;33:607-614.
45. Geeraerts B, Mimidis K, van Oudenhove L, et al. Role of endogenous opioids in the control of gastric sensorimotor function. Neurogastroenterol Motil 2008;20:1094-1102.
46. Geeraerts B, Van Oudenhove L, Boesmans W, et al. Influence of acute tryptophan depletion on gastric sensorimotor function in humans. Am J Physiol Gastrointest Liver Physiol 2011;300:G228-G235.
47. Holtmann G, Siffert W, Haag S, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004;126:971-979. (Pubitemid 38451168)
48. Oshima T, Nakajima S, Yokoyama T, et al. The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med Genet 2010;11:13.
49. Tahara T, Shibata T, Wang F, et al. Genetic polymorphisms of molecules associated with innate immune responses, TRL2 and MBL2 genes in Japanese subjects with functional dyspepsia. J Clin Biochem Nutr 2010;47:217-223.
50. Tahara T, Shibata T, Nakamura M, et al. Homozygous TRPV1 315C influences the susceptibility to functional dyspepsia. J Clin Gastroenterol 2011;44:e1-e7.
51. Ang D, Talley NJ, Simren M, et al. Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther 2011;33:634-649.
52. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008;8:690-696.
53. Coffin B, Bortolloti C, Bourgeois O, Denicourt L. Efficacy of a simethicone, activated charcoal and magnesium oxide combination (Carbosymag (®)) in functional dyspepsia: results of a general practice-based randomized trial. Clin Res Hepatol Gastroenterol 2011;35:494-499.
54. Hsu YC, Liou JM, Yang TH, et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J Gastroenterol 2011;46:183-190.
55. Chen SL, Ji JR, Xu P, et al. Effect of domperidone therapy on nocturnal dyspeptic symptoms of functional dyspepsia patients. World J Gastroenterol 2010;16:613-617.
56. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007: CD003960 [review].
57. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotilitylike functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008;103:1906-1919.
58. Chey WD, Howden CW, Tack J, et al. Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. Dig Dis Sci 2010;55:684-697.
59. Tack J, Janssen P, Bisschops R, et al. Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia. Neurogastroenterol Motil 2011;23:e32-e39.
60. Tack J, Janssen P. Emerging drugs for functional dyspepsia. Expert Opin Emerg Drugs 2011;16:283-292.
61. Suzuki H, Hibi T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol Motil 2010;22:595-599.
62. Tack J, Janssen P. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia. Expert Opin Investig Drugs 2011;20:701-712.
63. Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther 2011;336:791-800.
64. Yoshii K, Hirayama M, Nakamura T, et al. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. J Pharm Sci 2011. doi: 10.1002/jps.22649. [Epub ahead of print]
65. Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-e173. This study reports the phase 2 data with acotiamide in functional dyspepsia. The response profile in these studies determined patient, endpoint and dose selection for phase 3 trials.
66. Matsueda K, Hongo M, Tack J, et al. Efficacy and safety of acotiamide (Z-338) administered orally for 4-weeks in patients with functional dyspepsia: results from a randomized, double-blind, placebo-controlled phase III trial in Japan. Gastroenterology 2011;140(Suppl 1):S-30 (abstract).
67. Shiratori M, Shoji T, Kanazawa M, et al. Effect of Rikkunshito on gastric sensorimotor function under distention. Neurogastroenterol Motil 2011;23:323-e156.
68. Kusunoki H, Haruma K, Hata J, et al. Efficacy of Rikkunshito, a traditional Japanese medicine (Kampo), in treating functional dyspepsia. Intern Med 2010;49:2195-2202.
69. Suzuki H, Inadomi JM, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil 2009;21:688-696.
70. Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology 2010;151:3773-3782.